4//SEC Filing
Reardon Tighe 4
Accession 0001415889-24-015676
CIK 0001817713other
Filed
Jun 4, 8:00 PM ET
Accepted
Jun 5, 7:23 PM ET
Size
9.5 KB
Accession
0001415889-24-015676
Insider Transaction Report
Form 4
Reardon Tighe
Acting Chief Financial Officer10% Owner
Transactions
- Sale
Common Stock
2024-06-03$54.75/sh−131,196$7,182,981→ 633,673 total(indirect: By Avalon BioVentures I, LP) - Sale
Common Stock
2024-06-03$54.75/sh−691,525$37,860,994→ 3,340,018 total(indirect: By Avalon BioVentures SPV I, L.P.)
Holdings
- 174,989
Common Stock
Footnotes (4)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.75 to $55.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The shares are directly held by Avalon BioVentures I, LP ("ABV I"). Avalon BioVentures GP LLC ("ABV GP") is a general partner of ABV I and may be deemed to have voting and investment power with respect to the shares held by ABV I and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV GP and shares voting and investment power with respect to the shares held by ABV I. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
- [F3]The shares are directly held by Avalon BioVentures SPV I, LP ("ABV SPV"). ABV SPV I GP LLC ("ABV SPV GP") is a general partner of ABV SPV and may be deemed to have voting and investment power with respect to the shares held by ABV SPV and as a result may be deemed to have beneficial ownership of such shares. The Reporting Person is a managing member of ABV SPV GP and shares voting and investment power with respect to the shares held by ABV SPV. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his actual pecuniary interest therein, if any.
- [F4]The shares held directly by the Reporting Person prior to the transactions reported herein reflect the receipt of shares pursuant to the pro rata distributions in kind, effected by each of ABV I and ABV SPV to its general partner and limited partners for no additional consideration, and the further pro rata distribution in kind by the general partners of ABV I and ABV SPV, for no additional consideration to their members, including the Reporting Person. The receipt of such shares by the Reporting Person constituted a change in form of ownership from indirect to direct, which was exempt from reporting pursuant to Rule 16a-13.
Documents
Issuer
Janux Therapeutics, Inc.
CIK 0001817713
Entity typeother
Related Parties
1- filerCIK 0001760431
Filing Metadata
- Form type
- 4
- Filed
- Jun 4, 8:00 PM ET
- Accepted
- Jun 5, 7:23 PM ET
- Size
- 9.5 KB